Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohnʼs disease: A prospective pilot study

Infliximab therapy showed clear suppressive effects on clinical and endoscopic disease activity, and mucosal cytokine production in patients with early endoscopic lesions after resection. To confirm our conclusions, randomized controlled trials with a larger number of patients are necessary.